A novel drug delivery system for controlled release of aspirin

October 12, 2017, Indian Institute of Science
Credit: Dasgupta et al.

An interdisciplinary team of researchers at the Indian Institute of Science has designed a novel chemical compound that can be tailored to release aspirin over a desired duration inside the body. It also has several advantages over existing mechanisms: It is harmless to living cells, can carry a large amount of the drug, and can easily be injected.

Commonly used pills or patches have trapped inside a capsule or a mesh. The new compound, however, has aspirin built directly into the backbone of a long chain with a sugar molecule called as the base. Xylitol is naturally found in fruits and vegetables, and used as a sweetener. As the bond between xylitol and the drug is slowly broken down by the body's enzymes, the drug will gradually diffuse into the bloodstream.

"Unlike pills that release all the drug at the same time, this would allow the molecule to circulate longer and have a more prolonged effect," says Kaushik Chatterjee, one of the authors of the paper published in the International Journal of Pharmaceutics.

Aspirin is best known for reducing fever and pain. This household drug can also lower the risk of heart attack or stroke by preventing clots from forming in blood vessels. Previous research has shown that a gradual release of aspirin instead of a rapid initial burst can stave off unwanted side effects. A single compound that circulates in the body and releases a certain amount of aspirin periodically may also provide an alternative to taking multiple pills at different times.

In recent years, scientists have turned to polymers—large molecules with repeating units—to develop slow-release systems with the drug built in. Ideally, such a compound should also be harmless to living cells and be able to carry a large amount of drug.

In this study, the researchers picked a sugar alcohol called xylitol as its base because it meets all the above requirements. For one, it forms degradable polymers that can break down slowly inside the body, giving the drug a longer time to diffuse. It also has more free sites for the drug to bind than other alcohols.

"Another major advantage is that it is entirely biodegradable," says first author Queeny Dasgupta, PhD student at the Centre for Biosystems Science and Engineering. "All the precursors used to make the polymer are endogenous (native) to the body so there is no accumulation." Xylitol is also relatively unreactive and unlikely to interfere with aspirin's action.

However, previously developed xylitol-based polymers have a drawback. During synthesis, they form complex mesh-like structures (crosslinked polymers) that are difficult to dissolve and inject, and have to be surgically implanted inside the body.

In the current study, the researchers modified the reaction conditions in such a way that xylitol was forced to form a long, straight chain that can easily be dissolved into a gel and injected. "The linear chain is important because only then can you inject it. Once it forms a network, it becomes a solid lump that is implantable but not injectable," says Chatterjee. The linear polymerization was achieved using a novel technique.

The researchers found that their compound was able to release about 8% of the drug in the first week, 13% in the second and 20% by four weeks. When tested with blood cells in the lab, the released drug was able to reduce inflammation—a key reaction in reducing pain—as expected.

By tweaking the type of chemical bonds and number of free sites that the compound has, the timing and dose of delivery can be adjusted, the authors say. "For example, if you want low doses of aspirin over sustained periods, say weeks, then you may want to have more such bonds that would not degrade so easily," says Chatterjee.

The technique can also be used to develop similar delivery vehicles for other drugs with sustained and tunable release, the researchers say.

Explore further: Good and bad news on aspirin and colon cancer: study

More information: Controlled release from aspirin based linear biodegradable poly(anhydride esters) for anti-inflammatory activity, International Journal of Pharmaceutics, August 2017. www.sciencedirect.com/science/ … ii/S0378517317305732

Related Stories

Good and bad news on aspirin and colon cancer: study

September 6, 2017
Daily aspirin use—known to reduce the risk of colon cancer—could also make the disease harder to treat if it does occur, researchers reported Wednesday.

Daily aspirin regimen not safe for everyone, FDA warns

May 6, 2014
(HealthDay)—Taking an aspirin a day can help prevent heart attack and stroke in people who have suffered such health crises in the past, but not in people who have never had heart problems, according to the U.S. Food and ...

Can regular aspirin use reduce your cancer risk?

May 31, 2017
Most of us have likely taken aspirin at some point in our lives for a common minor ailment like headaches, fever or muscle cramps. Research has also shown this drug to be an effective part of treatment for heart attacks and ...

Recommended for you

Medicating distress: Risky sedative prescriptions for older adults vary widely

October 18, 2018
Despite years of warnings that older adults shouldn't take sedative drugs that put them at risk of injury and death, a new study reveals how many primary care doctors are still prescribing them, how often, and exactly where.

Medical management of opioid-induced constipation differs from other forms of condition

October 17, 2018
Traditional laxatives are recommended as first-line agents to treat patients with a confirmed diagnosis of opioid-induced constipation (OIC), according to a new guideline from the American Gastroenterological Association ...

Research assesses geographic distribution of new antibiotics following market introduction

October 16, 2018
There is a growing need for new antibiotics to help combat the looming threat of antimicrobial resistance. According to a new study conducted by researchers at the Center for Disease Dynamics, Economics & Policy (CDDEP) with ...

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

Do price spikes on some generic drugs indicate problems in the market?

October 1, 2018
A new USC study reports that sudden price spikes for some generic drugs—such as the recently reported increases of a decades-old generic heart medication and an antibiotic—are becoming more common.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.